Breaking news about Abzu and our achievements with scientific AI.
Abzu® and Contera Pharma expand strategic partnership to add target identification to RNA therapeutic design platform.
The application designs RNA therapeutics through parallel hypotheses testing of drug targets and individual antisense oligonucleotide (ASO) drug properties.
The U.S. Patent and Trademark Office issues patent for the technology behind the pioneering QLattice® algorithm.
Abzu® announced that the United States Patent and Trademark Office (USPTO) has issued Abzu Aps a patent number US 11,537,686 titled “Method of Deriving a Correlation” that protects the technology behind the pioneering QLattice algorithm.
Abzu® becomes a vetted member of the Nordic Ethical AI Landscape.
Launched in collaboration with the Ethical AI Governance Group (EAIGG) and the Ethical AI Database (EAIDB), the Nordic Ethical AI Landscape is the only publicly available, vetted database of AI companies in the Nordics that provide ethical services.
Abzu® selected partner for EU project Elegant North to create a new strategy for handling data on rare diseases.
To address the deficiency of treatments for rare diseases, the selected partners in project Elegant North will create a cross-border, rare disease data-sharing platform to foster cross-sector collaboration between researchers, companies, and healthcare systems.
Abzu® reveals insights in first-ever clinically viable Myc oncogene inhibitor by Peptomyc®.
Peptomyc used the QLattice and Abzu’s expertise in patient stratification to reveal early predictive response-biomarkers to treatment with OMO-103 in metastatic patients. The analysis by the QLattice was conducted on a very small clinical trial of 22 patients.
Abzu® awarded multi million EIC Accelerator grant.
Abzu will be applying the €2.5 million grant to the development of the Abzu AI platform, a user-friendly and easy-to-operate platform built on the QLattice engine that makes interpretable and explainable predictions widely accessible.
Abzu® is named a 2022 Gartner® “Cool Vendor”.
Abzu is named a “Cool Vendor” in the 2022 Gartner Cool Vendors in AI Governance and Responsible AI — From Principles to Practice report, an annual evaluation of commercial platforms for data science and machine learning (ML), as well as for cloud AI services platforms.
Abzu® appoints Mette Kirstine Agger as a board member.
Mette Kirstine Agger will help Abzu strengthen its position in life science and biotech by building a bridge between research and business development with her special experience in how new technologies can create and support growth and business opportunities within biotech and a wide range of other lines of industries.
Abzu® announces a new location at the Switzerland Innovation Park Basel Area – Novartis Campus.
Basel Area Business & Innovation, a non-profit agency dedicated to helping startups, institutions, and companies find business success in the Basel Area, was integral in supporting Abzu’s settlement and facilitating access to the thriving ecosystem.
Abzu® and Contera Pharma partner to design RNA therapeutics for rare diseases with explainable AI.
The two companies aim to have a rapid target screening application available this year, enabling Contera Pharma to advance better nucleic acid-based therapeutics towards clinic development.
Record-breaking investment in groundbreaking Danish AI: Abzu® announces a € 5.8 million seed round.
Prior to the record-breaking seed round in Denmark of € 5.8 M, Abzu raised a total of € 2.9 M. Abzu plans to accelerate commercialization within pharmaceutical drug discovery and mature its AI platform for application in other industry verticals.
Abzu® selected to join the Endless Frontier Labs 2020 – 2021 cohort.
Jonas Wilstrup, co-founder, CFO, and COO at Abzu, says, “It is an exciting step for Abzu that the NYU Stern School of Business has chosen us to be part of the Endless Frontier Labs program. We are truly breaking the mold with our unique and game-changing approach to AI, and we are over the moon that we are the only Nordic AI company to be selected to the program this year.”
Two Danish startups fight false news using artificial intelligence.
The transparent and explainable graph-based models from Abzu allow Byrd to precisely understand what inputs have been used to determine if content has been falsified.
Abzu® receives 1 million DKK grant for innovative, explainable AI.
Abzu’s proprietary innovation completely changes the way problems are solved by introducing a new standard of interpretability. This funding will be used for research and product development.
Invite-only launch of Abzu’s pioneering AI receives positive feedback.
“My skepticism towards machine learning is that people apply very complicated models with lots of features to problems that are probably easier to solve. What I like about your product is that it takes into consideration that simpler models could also be a solution,” commented a user.
European startup aims to break the US and Chinese AI dominance.
Copenhagen- and Barcelona-led startup Abzu® is creating a SaaS platform that automatically builds advanced AI solutions, bringing AI to a much broader space of customers.